Drugging p53 in cancer: one protein, many targets.

Abstract excerpt

Mutations in the TP53 tumour suppressor gene are very frequent in cancer, and attempts to restore the functionality of p53 in tumours as a therapeutic strategy began decades ago. However, very few of these drug development programmes have reached late-stage clinical trials, and no p53-based therapeutics have been approved in the USA or Europe so far. This is probably because, as a nuclear transcription factor,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Europe
• Share to Mutation
• Share to Neoplasms